Targeting Notch enhances the efficacy of ERK inhibitors in BRAFV600E melanoma

Oncotarget

Volumn 7, Issue 44, 2016, Pages 71211-71222

  Krepler, Clemens ^a   Xiao, Min ^a   Samanta, Minu ^a   Vultur, Adina ^a   Chen, Hsin Yi ^a   Brafford, Patricia ^a   Reyes Uribe, Patricia I ^a   Halloran, Molly ^a   Chen, Thomas ^a   He, Xu ^a   Hristova, Denitsa ^a   Liu, Qin ^a   Samatar, Ahmed A ^b   Davies, Michael A ^c   Nathanson, Katherine L ^d   Fukunaga Kalabis, Mizuho ^a   Herlyn, Meenhard ^a   Villanueva, Jessie ^a  

^a WISTAR INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRAF; ERK; Melanoma; Notch; Targeted therapy resistance

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SCH 772984; UNCLASSIFIED DRUG; B RAF KINASE; INDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; SCH772984; SECRETASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; REVERSE PHASE PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUNEL ASSAY; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDAZOLES; MELANOMA; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RECEPTORS, NOTCH;

EID: 84995468913     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12078     Document Type: Article

References (43)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9-29
2. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150(2):251-263
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-954
4. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012; 44(9):1006-1014
5. Sullivan RJ and Flaherty KT. Major therapeutic developments and current challenges in advanced melanoma. British Journal of Dermatology. 2014; 170(1):36-44
6. Trunzer K, Pavlick A, Schuchter L, Gonzalez R, McArthur G, Hutson T, Moschos S, Flaherty K, Kim K, Weber J, Hersey P, Long G, Lawrence D, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of clinical oncology. 2013; 31(14):1767-1774
7. Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther. 2012; 11(5):1143-1154
8. Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discovery. 2013
9. Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford RF and Rizos H. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology. 2014; 8(3):544-554
10. Samatar AA and Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nature reviews Drug discovery. 2014; 13(12):928-942
11. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011; 71(7):2750-2760
12. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 2012; 31(4):446-457
13. Deng W, Vashisht Gopal YN, Scott A, Chen G, Woodman SE and Davies MA. Role and therapeutic potential of PI3KmTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell & Melanoma Research. 2012; 25(2):248-258
14. AtefiM, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS and Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by cotargeting the AKT/mTOR pathway. PLoS ONE. 2011; 6(12):e28973
15. Nathanson K, Martin A-M, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, O'Day S, Infante J, Falchook G, Arkenau H-T, Millward M, Brown M, Pavlick A, et al. Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical cancer research. 2013; 19(17):4868-4878
16. Tibes R, Qiu Y, Lu Y, Hennessy B, AndreeffM, Mills GB and Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Molecular Cancer Therapeutics. 2006; 5(10):2512-2521
17. Tolcher A, Messersmith W, Mikulski S, Papadopoulos K, Kwak E, Gibbon D, Patnaik A, Falchook G, Dasari A, Shapiro G, Boylan J, Xu Z-X, Wang K, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. Journal of clinical oncology. 2012; 30(19):2348-2353
18. Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, Shang S, Pavlick A, Shao Y, Darvishian F, Boylan JF, Osman I and Hernando E. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One. 2011; 6(9):e25264
19. Nair JS, Sheikh T, Ho AL and Schwartz GK. PTEN regulates sensitivity of melanoma cells to RO4929097, the gamma-secretase inhibitor. Anticancer Res. 2013; 33(4):1307-1316
20. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014; 20(7):1965-1977
21. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW and Stern DF. Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening. Cancer Discovery. 2013; 3(1):52-67
22. Bedogni B, Warneke JA, NickoloffBJ, Giaccia AJ and Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. The Journal of clinical investigation. 2008; 118(11):3660-3670
23. Liu Z-J, Xiao M, Balint K, Smalley K, Brafford P, Qiu R, Pinnix C, Li X and Herlyn M. Notch1 signaling promotes primary melanoma progression by activating mitogenactivated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Research. 2006; 66(8):4182-4190
24. Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res. 2009; 69(13):5312-5320
25. Reedijk M. Notch signaling and breast cancer. Advances in experimental medicine and biology. 2012; 727:241-257
26. Ahn S, Hyeon J and Park CK. Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary & pancreatic diseases international. 2013; 12(3):286-294
27. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, Kalemkerian GP and Wicha MS. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res. 2013; 19(8):1972-1980
28. Theys J, Yahyanejad S, Habets R, Span P, Dubois L, Paesmans K, Kattenbeld B, Cleutjens J, Groot AJ, Schuurbiers OC, Lambin P, Bussink J and Vooijs M. High NOTCH activity induces radiation resistance in non small cell lung cancer. Radiotherapy and oncology. 2013; 108(3):440-445
29. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, et al. Notch3 Pathway Alterations in Ovarian Cancer. Cancer Res. 2014
30. Forloni M, Dogra SK, Dong Y, Conte D, Ou J, Zhu LJ, Deng A, Mahalingam M, Green MR and Wajapeyee N. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. eLife. 2013; 3
31. Capaccione KM and Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013; 34(7):1420-1430
32. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer cell. 18(6):683-695
33. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012; 487(7408):505-509
34. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, et al. Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487(7408):500-504
35. Andersson ER, Sandberg R and Lendahl U. Notch signaling: simplicity in design, versatility in function. Development (Cambridge, England). 2011; 138(17):3593-3612
36. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D and Sarkar FH. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochimica et biophysica acta. 2010; 1806(2):258-267
37. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, Rudolf M, Siziopikou K, Kast WM, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002; 8(9):979-986
38. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE and Garraway LA. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013; 504(7478):138-142
39. D'Souza B, Miyamoto A and Weinmaster G. The many facets of Notch ligands. Oncogene. 2008; 27(38):5148-5167
40. Thomas RK, Baker AC, DeBiasi RM, Winckler W, LaFramboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill LE, Lee JC, Nicoletti R, Hatton C, et al. Highthroughput oncogene mutation profiling in human cancer. Nat Genet. 2007; 39(3):347-351
41. Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E and Herlyn M. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol. 2005; 166(5):1541-1554
42. Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty PA, Wilson M, Hayden J, Keeney F, Nathanson KL and Herlyn M. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene. 2014; 33(14):1850-1861
43. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England: 1990). 2008; 45(2):228-247